Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2021
June 2021, Vol 12, No 3
June 2021, Vol 12, No 3
Tebentafusp Extends Survival in Patients with Metastatic Uveal Melanoma
By
Phoebe Starr
AACR Meeting Highlights
June 2021, Vol 12, No 3
Treatment with tebentafusp (IMCgp100), a novel bispecific T-cell receptor (TCR) fusion protein, extended survival in patients with metastatic uveal melanoma, according to the results from a recent phase 3 trial.
Read More
Current and Future Effects of the COVID-19 Pandemic on Cancer Care
By
Phoebe Starr
COVID-19
June 2021, Vol 12, No 3
The COVID-19 pandemic caused significant disruptions to virtually all aspects of oncology care. There has been a steep drop in cancer diagnoses and screenings—a result of shelter-in-place policies instituted early on, as well as ongoing patient fears about returning to healthcare facilities for new appointments or follow-up care. Experts predict that there will soon be a surge of patients with advanced cancer, which has the potential to overwhelm a healthcare infrastructure already stretched very thin. There are also unanswered questions regarding the role of telemedicine moving forward, as well as the use of alternate sites of care. These issues were addressed by a panel of healthcare experts during the virtual National Comprehensive Cancer Network 2021 Annual Conference.
Read More
Recent Progress in the Biomarker Landscape for Gastrointestinal Malignancies
By
Nicholas J. Sarlis, MD, PhD, FACP
Gastrointestinal Cancers
June 2021, Vol 12, No 3
Gastrointestinal (GI) malignancies account for 26% of the global cancer incidence and 35% of all cancer-related deaths.
1
There is an urgent need for new therapeutic options for patients with advanced disease beyond the standard, highly burdensome combinatorial approach of polychemotherapy, radiotherapy, and surgery.
1
Recent advances in tumor molecular profiling are transforming the therapeutic landscape for patients with GI cancers, allowing for prognostication and predictive risk assessment, as well as more individualized regimens that can extend survival while minimizing the side effects that have long been associated with existing “legacy” treatment options.
Read More
The Alliance for Innovation in Integrated Healthcare Provides New Forum for Stakeholders
By
Phoebe Starr
Value-Based Care
June 2021, Vol 12, No 3
In recent years, the pace of innovation in healthcare has accelerated dramatically, ushering in new processes, therapies, technologies, and policies designed to increase efficiency, reduce waste, lower the cost of care, and improve clinical outcomes and quality of life for patients. However, along the way, stakeholders have encountered numerous obstacles that threaten to undermine the full potential of these advances. One of the most significant challenges is the fact that the development of innovation is frequently siloed, occurring within a specific subsector of the healthcare delivery ecosystem, with little consideration of the impact to other parts of the overall system.
Read More
Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation
FDA Approvals, News & Updates
,
Lung Cancer
June 2021, Vol 12, No 3
On
May 28, 2021
, the FDA accelerated the approval of sotorasib (Lumakras; Amgen), an oral KRAS inhibitor of the RAS GTPase family, for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) associated with KRAS G12C mutation, as determined by an FDA-approved test, after ≥1 systemic therapies. The FDA granted sotorasib orphan drug and breakthrough therapy designations.
Read More
Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations
FDA Approvals, News & Updates
,
Lung Cancer
June 2021, Vol 12, No 3
On
May 21, 2021
, the FDA accelerated the approval of amivantamab-vmjw (Rybrevant; Janssen/Johnson & Johnson), a bispecific antibody targeting mutations in the
EGFR
and MET pathways, for adults with non–small-cell lung cancer (NSCLC) that is associated with
EGFR
exon 20 insertion mutations, as detected by the FDA-approved Guardant360 CDx test, which was approved on the same day as a companion diagnostic for amivantamab. The FDA had granted amivantamab a breakthrough therapy designation for this indication.
Read More
Zynlonta First FDA-Approved CD19-Directed Therapy for Large B-Cell Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
June 2021, Vol 12, No 3
On
April 23, 2021
, the FDA accelerated the approval of loncastuximab tesirine-lpyl (Zynlonta; ADC Therapeutics SA), an intravenous, CD19-directed antibody and alkylating agent conjugate, for the treatment of relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma, in adults who have received ≥2 lines of systemic therapy.
Read More
Keytruda Received FDA Approval for First-Line Treatment of HER2-Positive Advanced Gastric Cancer
FDA Approvals, News & Updates
,
Gastric Cancer
June 2021, Vol 12, No 3
On
May 5, 2021
, the FDA accelerated the approval of the PD-1 inhibitor pembrolizumab (Keytruda; Merck & Co), in combination with trastuzumab plus fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Read More
Opdivo First FDA-Approved Immunotherapy for First-Line Treatment of Advanced Gastric Cancer
FDA Approvals, News & Updates
,
Gastric Cancer
June 2021, Vol 12, No 3
On
April 16, 2021
, the FDA approved the PD-1 inhibitor nivolumab (Opdivo; Bristol Myers Squibb), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or esophageal adenocarcinoma. Nivolumab was the first immunotherapy approved by the FDA for first-line treatment of gastric cancer.
Read More
Selpercatinib Demonstrates Promising Activity in a Variety of RET Fusion–Positive Solid Tumor Types
By
Phoebe Starr
AACR Meeting Highlights
June 2021, Vol 12, No 3
Selpercatinib (Retevmo) demonstrated antitumor activity in
RET
fusion–positive tumors other than lung cancer and thyroid cancer, according to interim results from the phase 1/2 LIBRETTO-001 clinical trial. Results from the trial were presented by Vivek Subbiah, MD, Medical Director, Clinical Center for Targeted Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, at the 2021 virtual American Association for Cancer Research annual meeting.
Read More
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma